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A B S T R A C T   
The presence of diclofenac in the aquatic environment and the risks for aquatic wildlife, especially fish, have 
been raised in several studies. One way to manage risks without enforcing improved wastewater treatment 
would be to substitute diclofenac (when suitable from a clinical perspective) with another non-steroidal anti- 
inflammatory drug (NSAID) associated with less environmental risk. While there are many ecotoxicity-studies 
of different NSAIDs, they vary extensively in set-up, species studied, endpoints and reporting format, making 
direct comparisons difficult. We previously published a comprehensive study on the effects of diclofenac in the 
three-spined stickleback (Gasterosteus aculeatus). Our present aim was to generate relevant effect data for 
another NSAID (naproxen) using a very similar setup, which also allowed direct comparisons with diclofenac 
regarding hazards and risks. Sticklebacks were therefore exposed to naproxen in flow-through systems for 27 
days. Triplicate aquaria with 20 fish per aquarium were used for each concentration (0, 18, 70, 299 or 1232 
μg/L). We investigated bioconcentration, hepatic gene expression, jaw lesions, kidney and liver histology. On 
day 21, mortalities in the highest exposure concentration group unexpectedly reached ≥ 25 % in all three 
replicate aquaria, leading us to terminate and sample that group the same day. On the last day (day 27), the 
mortality was also significantly increased in the second highest exposure concentration group. Increased renal 
hematopoietic hyperplasia was observed in fish exposed to 299 and 1232 μg/L. This represents considerably 
higher concentrations than those expected in surface waters as a result of naproxen use. Such effects were 
observed already at 4.6 μg/L in the experiment with diclofenac (lowest tested concentration). Similar to the 
responses to diclofenac, a concentration-dependent increase in both relative hepatic gene expression of c7 
(complement component 7) and jaw lesions were observed, again at concentrations considerably higher than 
expected in surface waters. Naproxen bioconcentrated less than diclofenac, in line with the observed effect 
data. An analysis of recent sales data and reported concentrations in treated sewage effluent in Sweden suggest 
that despite higher dosages used for naproxen, a complete substitution would only be expected to double 
naproxen emissions. In summary, naproxen and diclofenac produce highly similar effects in fish but the en-
vironmental hazards and risks are clearly lower for naproxen. Hence, if there are concerns for environmental 
risks to fish with diclofenac, a substitution would be advisable when naproxen presents an adequate alter-
native from a clinical point-of-view.   
1. Introduction 
In the last decades, there has been an increasing concern about 
pharmaceuticals in the environment and the effects they can have on 
non-target organisms. Diclofenac, a commonly used non-steroidal anti- 
inflammatory drug (NSAID) has received much attention for being the 
culprit in the near extinction of several vulture species in Pakistan 
(Oaks et al., 2004; Prakash et al., 2012). Effects of diclofenac on a range 
of aquatic organisms have been studied as well (Cleuvers, 2003;  
Schwaiger et al., 2004; Ericson et al., 2010; Näslund et al., 2017;  
Yokota et al., 2018). 
Cytological effects in kidneys and other organs of salmonid fish have 
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been reported at concentrations down to 1 μg/L (Triebskorn et al., 
2004). Diclofenac concentrations in treated sewage effluents are gen-
erally below (Loos et al., 2013) or around 1 μg/L (Brown et al., 2007;  
Fick et al., 2010a; Meyer et al., 2016) and similar concentrations have 
been reported in surface water (Lacina et al., 2013; Marsik et al., 2017). 
Together, these findings have led to concerns for effects on wild fish and 
the inclusion of diclofenac as one of the first pharmaceuticals on the 
watch list of priority substances within the European Water Framework 
Directive (EU, 2013). However, some studies, funded by a company 
marketing diclofenac, has challenged the initial reports (Memmert 
et al., 2013; Wolf et al., 2014). These studies reported a No Observed 
Effect Concentration (NOEC) of 320 μg/L on fish. Independently, we 
conducted a study showing that diclofenac caused histological changes 
in the three-spined stickleback already at the lowest tested concentra-
tion (4.6 μg/L) following a clear concentration-response pattern, and 
with significant mortality occurring at 271 μg/L (Näslund et al., 2017). 
The European Commission recently concluded that diclofenac should 
be removed from the watch list due to “sufficient high-quality mon-
itoring data” (EU, 2018). There is still no official information whether 
or not diclofenac will be included on the priority substances list in the 
Water Framework Directive. If an Environmental Quality Standard is 
set for diclofenac, large investments may be required to reduce emis-
sions from wastewater treatment plants (WWTPs). 
An alternative or additional way to decrease the concentration of 
diclofenac in effluents that does not involve upgrading wastewater 
treatment is to reduce incoming amounts of diclofenac. As several 
NSAIDs with largely similar effects are available, it is plausible that 
some of these could be used as clinically equivalent alternatives to di-
clofenac in many situations. In fact, different countries tend to use 
different NSAIDs in very different proportions (Kookana et al., 2014). A 
“replacement drug”, should not only provide the desired effects on the 
patient without increasing risks for side effects. Evidence should also 
exist that the risks for adverse environmental effects indeed would be 
reduced. Naproxen is a frequently used over-the-counter drug, and it is 
the first-line NSAID treatment of e.g. nociceptive pain and in-
flammatory joint diseases in Sweden (Janusinfo Region Stockholm, 
2020). Naproxen could probably quite often be a realistic substitute to 
diclofenac from a clinical point of view (Coxib and traditional NSAID 
Trialists' (CNT) Collaboration, 2013; van Walsem et al., 2015; Schmidt 
et al., 2018). However, it should be noted that NSAIDs differ in both 
potency and side effects, but in practice, they are often marketed and 
used for the same indications, particularly with regards to over-the- 
counter use. Fish appears to be the most sensitive aquatic organism to 
NSAIDs, but the effects of naproxen are sparsely investigated (Stancova 
et al., 2015a; Li et al., 2016; Sehonova et al., 2017; Kwak et al., 2018;  
Xu et al., 2019). The data on histopathological effects is even more 
limited with only three published studies to the best of our knowledge 
(Stancova et al., 2015a; Li et al., 2016; Sehonova et al., 2017). This 
incompleteness of data makes the risk evaluation for fish exposed to 
naproxen difficult. Other NSAIDs may also pose lower environmental 
risks than diclofenac, but a thorough evaluation of these is beyond the 
scope of this article. 
The primary aim of the present study was to generate relevant 
effect data on naproxen in fish and to do so in a way that allows a 
direct comparison with diclofenac regarding their environmental ha-
zards and risks. Based on existing studies, it is difficult to draw firm 
conclusions on their relative potency due to different endpoints ana-
lyzed in different ways, in different labs, in different species and under 
highly variable exposure conditions. To facilitate a more direct com-
parison, we therefore used a very similar study set-up with the three- 
spined stickleback as in our previous study on diclofenac (Näslund 
et al., 2017). Specifically, we investigated bioconcentration, growth, 
hepatic gene expression, macroscopic lesions and kidney and liver 
histology. 
2. Material and methods 
2.1. Animals 
Wild three-spined sticklebacks with no external signs of disease 
were collected by ring nets in Öresund on the Swedish southwest coast 
in February 2014. The fish was approximately 8–9 months old (con-
sidered juveniles). They were transported in well aerated tubs to the 
Aquatic Facility at Swedish University of Agricultural Sciences (SLU) 
in Uppsala where they were acclimatized to laboratory conditions by 
gradually replacing the water to carbon filtrated tap water and ad-
justing the temperature. A few fish from the batch were used for a 
parasitological investigation. Scrapings from gills, skin and fins were 
investigated via light microscopy and occasional protozoan parasites 
were found in some individuals. All fish were then treated with a di-
lute formaldehyde bath for one hour once to remove any external 
parasites. (2.5 mL 37 % formaldehyde to 10 L of water). A new 
parasitological investigation was performed afterwards in the same 
manner as previously described. No parasites were detected during the 
second investigation. The fish were kept in 100-L filtrated well-aer-
ated glass aquaria with continuous flow-through of new carbon-fil-
trated tap water. The temperature was approximately 13–14 °C and 
the fish were fed frozen bloodworms 1–2 times a day. The photoperiod 
was set to 8 h light and 16 h dark to keep the sticklebacks reproduc-
tively inactive. Fish were held under these conditions for approxi-
mately 2 months before the experiment started. An animal ethics 
permit was given in advance by the Uppsala Ethical Committee on 
Animal Research (C198/12). 
2.2. Test chemical 
Naproxen sodium salt (CAS: 26159-34-2, purity 98.0–102.0 %) was 
purchased from Sigma–Aldrich (Steinheim, Germany). 
2.3. Experimental design 
Before the start of the experiment, 300 sticklebacks were randomly 
distributed in 15 glass aquaria (size 54 L with 44 L of water, n = 20 
fish/aquarium). There was a continuous flow-through of carbon-fil-
trated, aerated tap water delivered by a multi-channel peristaltic pump 
(Ismatec®, Wertheim, Germany) with PharMed Ismaprene tubing in the 
pump and silicone tubing as extensions. Each aquarium was enriched 
with a glass jar made non-transparent by sandblasting and all aquaria 
had airstones to ensure appropriate oxygen levels in the water. For 
chemical characteristics of the tap water used, see supplementary data. 
Naproxen sodium was mixed with MilliQ water on a magnetic 
stirrer approximately 1–2 h in total darkness. No solvents were used. 
This created a ‘superstock' with the concentration of 1280 mg/L of 
naproxen. Aliquots from the superstock were diluted with MilliQ water 
to produce four different stock solutions (8 mg/L, 32 mg/L, 128 mg/L 
and 512 mg/L) with three replicates for each concentration so each 
aquarium had its own stock solution bottle. The control aquaria had 
only MilliQ water in their stock solution bottles. A multi-channel 
peristaltic pump (Ismatec®, Wertheim, Germany) with PharMed 
Ismaprene tubing in the pump and polytetrafluoroethylene (PTFE) 
tubing as extensions were used to deliver the stock solutions to the 
aquaria. The nominal concentrations in the aquaria were set to be 0 μg/ 
L, 20 μg/L, 80 μg/L, 320 μg/L and 1280 μg/L, with 3 replicate aquaria 
for each concentration. This created four different exposure con-
centration groups and one control group, each group containing three 
replicate aquaria (placed in mixed order). The superstock and stock 
solutions were renewed once a week. The concentrations were chosen 
so that there would be an overlap with the nominal concentrations used 
in our previous study on diclofenac (Näslund et al., 2017). The 
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concentration range, however, was shifted up one dilution step as the 
fish plasma model suggested lower potency of naproxen (Fick et al., 
2010b). The highest nominal concentration was more than 500 times 
lower than the reported LC50 in fish (Rodriguez et al., 1992) to reduce 
risks for direct, drug-induced mortalities. 
At the onset of the experiment (day zero), the pump delivering stock 
solutions was started and different volumes of the superstock were 
added manually to all but the control aquaria to immediately reach the 
target concentrations. The fish were fed frozen bloodworms 1–2 times 
daily and fecal matter was removed by siphoning two times a week. 
Temperature (15.0–16.6 °C) and oxygen level (≥ 97.1 %) were mea-
sured two times a week, and pH (8.11–8.25) on day 6 and 20. Water 
samples for determination of actual exposure concentrations were taken 
2–3 times a week and stored at −20 °C until analysis. 
The fish were checked daily and dead fish were removed. Moribund 
fish (included in mortality counts) were also removed and euthanized 
by decapitation followed by rapid destruction of the brain, in line with 
the approved ethical permit. Any external symptoms on the removed 
fish were noted. The experiment was planned to last 27 days. 
2.4. Sampling 
On day 21, the mortality had unexpectedly reached ≥25 % in all 
aquaria in the highest exposure concentration group (1280 μg/L, 
nominal) and that fish were sampled the same day due to animal 
welfare reasons. All of the other treatment groups were sampled as 
planned on day 27. The sampling was done as described in detail in 
paragraph 2.4 in Näslund et al. (2017) but due to a higher number of 
fish in each aquarium in the present study, four fish from each aqua-
rium, were used for analysis of whole-body naproxen concentration. 
2.5. Chemical analysis 
Chemical analysis is described in full detail in Näslund et al. (2017) 
and Grabic et al. (2012) using D3-naproxen as the internal standard. 
Briefly, naproxen concentration in water samples and in stickleback 
(whole-body) were measured using a triple stage quadrupole tandem 
mass spectrometry (MS/MS) TSQ Quantum Ultra EMR (Thermo Fisher 
Scientific, San Jose, CA, USA). Two pumps were used in the analytical 
system, an Accela and a Surveyor LC pump (Thermo Fisher Scientific, 
San Jose, CA, USA), and these were coupled with a PAL HTC auto-
sampler (CTC Analytics AG, Zwingen, Switzerland). Concentrations 
were reported per wet weight. 
2.6. Bioconcentration and condition factors 
Bioconcentration factors (BCFs) were calculated by dividing the 
average naproxen concentration of the four analyzed fish in each 
aquarium (whole-body; ng/g; wet weight (ww)) with the mean na-
proxen concentration in the water of the same aquarium (μg/L). 
Fulton´s condition factor was calculated by dividing the total weight (g) 
of the fish by the cube of the total length (cm) and multiplying the 
result with 100. 
2.7. Histological analysis 
The formalin-fixated fish were trimmed before sectioning. The head 
was removed caudally to the gills and the tail caudally to the anus. The 
spines on the back and the abdomen were cut away to facilitate sec-
tioning and the swim bladder was punctured to ensure paraffin pene-
tration. All abdominal organs were left in situ. The remaining body of 
the fish was put on its lateral side in plastic cassettes followed by 
routine processing and imbedding. The sectioning and staining proce-
dure were the same as in our previous study (Näslund et al., 2017). 
Presence of hematopoietic hyperplasia, tubular necrosis, pigmented 
macrophage aggregates (PMA), tubular regeneration, tubular hyaline 
degeneration/droplets and parasites were graded in the kidney. Pre-
sence of hepatocellular vacuolation, inflammatory cell foci, pigmented 
macrophage aggregates (PMA), hepatocellular necrosis and parasites 
were graded in the liver. A 4-point grading system was used with 0 = 
Not present, 1 = Minimal, 2 = Mild, 3 = Moderate and 4 = Severe. All 
slides were coded, leaving the pathologist (JN) unaware of the treat-
ment. The section with the largest part of the kidney was chosen for 
both the kidney and the liver assessment. Liver from a minimum of six 
fish and kidney from a minimum of eight fish from each aquarium were 
investigated. The different numbers were due to mortalities or in-
sufficient tissue for grading. For full details, see supplementary data. 
Before the start of the grading, a subset (20) of histological slides from 
stickleback kidney from Näslund et al. (2017) was reexamined blindly 
regarding renal hematopoietic hyperplasia (the only histological lesion 
with statistically significant differences between the exposure con-
centration groups and the control group from that study). This was 
done to ensure a comparable grading between the investigations. 
Ninety percent of the slides were assigned the same grade as the pre-
vious grading, which was considered acceptable. 
2.8. Quantitative real-time PCR 
Total RNA was extracted from livers from four individual stickle-
back per aquaria (two females and two males) using an RNeasy® Plus 
Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's re-
commendations. RNA quantity and quality was checked using the 
NanoDrop 2000c spectrophotometer (Thermo Scientific, Gothenburg, 
Sweden) and an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA, USA). Extracted RNA (1 μg) was reverse-transcribed 
to cDNA using the iScript® cDNA Synthesis Kit from Bio-Rad 
Laboratories, Inc. (Hercules, CA, USA) The following genes were se-
lected: cytochrome P450 1A (cyp1A), complement component 7 (c7), 
vitellogenin (vtg), glutathione reductase (gr) and superoxide dis-
mutase 1 (sod-1). The qPCR analyses were performed using 
SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad 
Laboratories, Inc., Hercules, CA, USA) with 10 ng of cDNA (in dupli-
cates) in a reaction volume of 10 μL. The primer concentration and 
annealing temperature were set to obtain efficiency between 95–105 
%. A protocol of melting (95 °C, 10 s), annealing and elongation (60 
°C, 30 s) was repeated for 40 cycles and followed by a final melting 
step to verify a single PCR product. No-template controls (NTC) and 
no-reverse transcriptase controls (NoRT) from random samples were 
used to check for primer dimer formation or DNA contamination. The 
mean CT of the duplicates were used. Quantitative PCR data were 
analyzed using 2−ΔΔCT method (Livak and Schmittgen, 2001) using β- 
actin (β-act) as reference gene, which was stable across treatment 
groups. For full details, see supplementary data. 
2.9. Statistical analysis 
The variation between fish within the same aquaria as well as the 
variation between aquaria within the same treatment was taken into 
account in the statistical analysis. Calculations were done in Stata 
(StataCorp. 2017. Stata Statistical Software: Release 15. College 
Station, TX: StataCorp LLC). Continuous data (length, weight, condi-
tion factor and normalized hepatic mRNA levels (ΔCT)) were analyzed 
by a mixed multilevel model with nominal naproxen aquarium con-
centration as a fixed factor and aquaria as a random factor. A mixed 
ordered logistic model was used for ordinal data (histological 
grading), again with nominal naproxen aquarium concentration as a 
fixed factor and aquaria as a random factor. Multiple comparisons 
were done according to Dunnett´s test with α = 0.05. Jaw lesions 
were analyzed by a mixed logistic model and a Poisson model was 
used for analysis of mortality data. A p-value of < 0.05 was con-
sidered significant. 
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3. Results 
3.1. Chemical analysis 
Nine water samples were analyzed from each aquarium except in 
the highest exposure concentration group where only seven samples 
were included due to the pre-termination of that group. Fifty-six fish 
samples were analyzed (four samples were lost during the preparation). 
Naproxen was not detected in any of the water or fish samples from the 
control group. The average measured naproxen concentrations per ex-
posure concentration group (calculated as the average of all analyzed 
samples within the same exposure concentration group) can be found in  
Table 1. The overall average bioconcentration factor was 0.07 and it 
was relatively stable across the entire range of exposure concentrations 
(Fig. 1; see supplementary data for full details). 
3.2. Mortality 
Eight moribund fish in six different aquaria were euthanized in 
advance during the experiment and are hereafter counted as mor-
talities. Fish in the two highest exposure concentration groups (299 μg/ 
L and 1232 μg/L, measured concentration) appeared to eat slower and 
even leave some food after approximately one week of exposure. After 
three weeks of exposure (day 21), the total mortality had unexpectedly 
reached ≥ 25 % in all three replicate aquaria in the highest exposure 
concentration group (1232 μg/L, measured). We therefore decided to 
terminate this group in advance due to animal welfare reasons, and the 
remaining fish were sampled the same day. The mortality was sig-
nificantly increased in that group compared to the control group 
(p < 0.001) (Fig. 2). At the end of the experiment (day 27), the second 
highest exposure concentration group (299 μg/L, measured), also 
reached a significantly increased mortality compared to the control 
group (p = 0.04) (Fig. 2) Full details can be found in the supplementary 
data. 
3.3. Jaw lesions 
Jaw lesions (Fig. 3) were observed among some of the dead or 
moribund fish removed during the experiment and at the sampling. It 
should be noted that none of the fish had any signs of jaw lesions before 
the start of the experiment. The overall prevalence was 22 % (67/300). 
In the two highest exposure concentration groups (299 μg/L and 1232 
μg/L), more than half of the fish had jaw lesions (Table 2). This was 
statistically significant compared to the control group (p < 0.001 for 
both groups, one-tailed test). Lesions were not observed in fish from any 
of the control aquaria and very few fish were affected in the 18 μg/L 
and 70 μg/L exposure concentration groups. For full details, see sup-
plementary data. 
3.4. Length, weight and condition factor 
Five fish were excluded from the statistical calculations for length, 
weight and condition factor due to caudal fin rot (four fish) or severe 
jaw lesion (one fish) resulting in non-comparable length estimates. 
There were no statistical significant differences in lengths between the 
different treatment groups. The weights of fish in the 299 μg/L and the 
1232 μg/L exposure concentration groups were lower compared to the 
control group (p = 0.042 and p < 0.001, respectively; two-tailed test; 
see supplementary data, Table S1). The fish in the highest exposure 
concentration group (1232 μg/L) had a lower condition factor com-
pared to the control group (p < 0.001; two-tailed test; see supplemen-
tary data, Table S1). For full details, see supplementary data. 
3.5. Histology 
3.5.1. Kidney 
The kidneys of 191 sticklebacks were examined histologically 
(8–16/aquarium). Renal hematopoietic hyperplasia was more extensive 
in fish from the 299 μg/L and the 1232 μg/L exposure concentration 
groups compared to the control group (p = 0.001 and p = 0.011, re-
spectively; one-tailed test based on previous literature (Schwaiger et al., 
2004; Näslund et al., 2017); Fig. 4). Note that fish exposed to the 
highest concentration were exposed for a shorter time. Micrographs of 
the different grades can be found in Fig. 5. Six fish (four in the control 
group, one in 18 μg/L group and one in the 70 μg/L group) had a 
moderate inflammation in their back musculature and one fish in the 
control group had a severe protozoan infection in the kidney. As such 
lesions probably could affect the renal hematopoietic hyperplasia and 
hence receive a higher grade (the median and mode grade for these 
seven fish were 3) one could argue that those fish should be removed 
from the statistical comparison. We performed an additional statistical 
analysis where these seven fish were excluded which resulted in an 
even stronger significant difference between the two highest exposure 
concentration groups and the control group (p < 0.001 and p = 0.001 
for 299 μg/L and 1232 μg/L respectively). Tubular necrosis was not 
found in any of the examined samples. None of the other graded renal 
Table 1 
Average measured naproxen concentrations in water (μg/L) and whole fish (ng/g ww).        
Naproxen concentration 
Nominal aquaria concentration (μg/L) 0 20 80 320 1280 
Measured concentration in water (μg/L; mean ± S.D.) (n1)  <  LOQ2 (27) 18 ± 2 (27) 70 ± 3 (27) 299 ± 15 (27) 1232 ± 67 (21) 
Measured concentration in fish (ng/g ww; mean ± S.D.) (n1)  <  LOQ3 (12) 1.7 ± 0.6 (11) 4.6 ± 2.7 (12) 20 ± 18 (10) 90 ± 37 (11) 
1 n = number of samples. 
2 LOQ = Limit of quantification 5 ng/L. 
3 LOQ = Limit of quantification 0.1 ng/g.  
Fig. 1. Bioconcentration factor (BCF; whole-body to water) in stickleback ex-
posed to naproxen. Grey bars show the average BCF of three aquarium re-
plicates + S.D. 
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lesions (pigmented macrophage aggregates, tubular regeneration, 
hyaline degeneration/droplets or parasites) showed any statistical sig-
nificant differences between the treatment groups. For full details, see 
supplementary data. 
3.5.2. Liver 
A total of 172 livers were examined (6–15/aquarium). Fish in the 
highest exposure concentration group (1232 μg/L) had a decreased 
hepatocellular vacuolation (p = 0.014, two-tailed test; Fig. 6). If the 
fish with the dorsal muscular inflammation mentioned above are re-
moved, the statistical significance of decreased hepatocellular vacuo-
lation is even stronger in the highest exposure concentration group 
(p < 0.001). Micrographs of the different grades can be found in Fig. 7. 
Note that the level of hepatocellular vacuolation often differ between 
species, gender, reproductive and nutritional status (Wolf and Wolfe, 
2005). Vacuolation can be very pronounced, especially in captive fish 
(Wolf and Wolfe, 2005) and hence, a basal level of grade 4, as found 
here, was considered normal. None of the other lesions examined (in-
flammatory cell foci, pigmented macrophage aggregates, hepatocellular 
necrosis and parasites) were statistically different between the treat-
ment groups. One fish from the highest exposure concentration group 
(1232 μg/L) was the only one that showed signs of hepatocellular ne-
crosis. Since a nematode was found in the abdomen of that specific fish, 
the hepatocellular necrosis could perhaps be due to previous parasite 
migration in the liver. For that reason, and due to the low prevalence, 
we interpret it as an incidental finding not related to the naproxen 
exposure. For full details, see supplementary data. 
3.6. Quantitative PCR 
Fifty-nine samples were analyzed for hepatic mRNA expression (one 
sample were lost during preparation in the group exposed to 18 μg/L). 
None of the previous mentioned sticklebacks with back inflammation 
were used. It was not possible to generate CT values for vtg in five 
samples (one from each treatment group), hence only 54 samples were 
Fig. 2. Measured naproxen concentration and mortality of exposed stickleback. Each grey bar represents the average naproxen concentration in one aquarium 
replicate + S.D. Asterisks indicate significant differences in mortality to the control group, * p = 0.04 (d. 27) and *** p < 0.001 (d. 21). 
Fig. 3. Formalin-fixated stickleback. A: Fish from control group with no signs of 
jaw lesions. B: Fish exposed to naproxen (1232 μg/L) with lesions on the lower 
jaw. 
Table 2 
Frequencies of jaw lesions in stickleback exposed to naproxen. 
Asterisks indicate significant differences to the control group, *** 
p < 0.001.    
Treatment group (μg/L) Fish with jaw lesions  
0 0/60 (0 %) 
18 1/60 (2 %) 
70 2/60 (3 %) 
299 31/60 (52 %) *** 
1232 33/60 (55 %) ***    
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included in the statistical comparison for that gene. The normalized 
hepatic mRNA expression (ΔCT) of c7 was higher in the two highest 
exposure concentration groups (299 μg/L and 1232 μg/L) compared to 
the control group (Fig. 8). The expression of cyp1A (Fig. 8), and sod-1 
(Fig. 8) were significantly lower in the highest exposure concentration 
group (1232 μg/L). The expression of gr was also significantly lower but 
only in the second highest exposure concentration group (299 μg/L;  
Fig. 8). One could argue that the lack of definite concentration-response 
for that gene makes the finding less reliable. However, it should be kept 
in mind that the fish in the highest exposure concentration group were 
exposed only 21 days compared to 27 days for all other treatment 
groups. Furthermore, there was a similar trend (p = 0.097) also in the 
highest exposure concentration group. There was no statistical differ-
ence between the exposure concentration groups and the control group 
for vtg (see supplementary data, Fig. S1). For full details, see supple-
mentary data. 
3.7. Comparison of diclofenac and naproxen 
Data on pharmacodynamic and pharmacokinetic properties as well 
as data relating to exposure in Swedish waters have been compiled for 
both diclofenac and naproxen (Table 3). In order to provide an 
Fig. 4. Grading of renal hematopoietic hyperplasia in stickleback exposed to naproxen, where grade 4 is the most severe hyperplasia. Asterisks indicate significant 
differences to the control group,* p = 0.011; *** p = 0.001. 
Fig. 5. Grading of renal hematopoietic hyperplasia in stickleback exposed to naproxen (magnification 200x). A: Grade 1, fish exposed to 0 μg/L; B: Grade 2, fish 
exposed to 18 μg/L; C: Grade 3, fish exposed to 299 μg/L; D: Grade 4, fish exposed to 1232 μg/L. 
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overview and be able to compare the results in this study with those in 
our previously published diclofenac study (Näslund et al., 2017), ex-
perimental design, lowest observed effect concentration (LOEC) and 
BCF for both NSAIDs are compiled in Table 4. Overall, the experimental 
designs were similar with exception of a higher number of fish in each 
aquarium in the naproxen study, and the concentration range tested 
was higher. The LOECs for naproxen were similar or higher for all 
endpoints. The most sensitive endpoint for diclofenac, renal hemato-
poietic hyperplasia, was significantly affected first at 65 times higher 
concentrations of naproxen. 
4. Discussion 
We show here that naproxen affects kidney histology and hepatic 
gene expression, and induces jaw lesions in fish in a similar way as 
diclofenac does. This is likely a reflection of both NSAIDs acting via a 
shared mode of action. That, in turn, suggest that the effects of diclo-
fenac and naproxen are expected to be additive in the case of co-ex-
posure (Backhaus, 2014). The most sensitive endpoint for diclofenac in 
our previous study (renal hematopoietic hyperplasia) was affected al-
ready at 4.6 μg/L - the lowest concentration tested (Näslund et al., 
2017). In the present study, naproxen caused similar changes, but first 
Fig. 6. Grading of hepatocellular vacuolation in stickleback exposed to naproxen where grade 4 is the most extensive vacuolation and in this study considered 
“normal”. Asterisks indicate significant differences to the control group, * p = 0.014. 
Fig. 7. Grading of hepatocellular vacuolation in fish exposed to naproxen (magnification 400x). A: Grade 4, fish exposed to 0 μg/L; B: Grade 3, fish exposed to 299 
μg/L; C: Grade 2, fish exposed to 1232 μg/L; D: Grade 1, fish exposed to 1232 μg/L. 
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at 299 μg/L, a 65-fold higher concentration. For other, less sensitive 
endpoints, the difference was smaller (still large for the change in he-
patic mRNA levels of the gene c7). It is possible that the effects on e.g. 
mortality and condition factor is a reflection of additional mechanisms 
of actions that become relevant only at higher exposure concentrations 
which are less plausible for fish to encounter. The similar potency in 
diclofenac and naproxen with regards to jaw lesions, a considerably 
more specific endpoint than mortality and condition factor, is then 
perhaps a bit surprising. It should however be pointed out that a recent 
study by Yokota et al. (2018) demonstrated concentration-response 
related mandibular defects of diclofenac at 26.5 μg/L in Japanese me-
daka, which is more than 10 times lower than the LOEC observed here 
for naproxen. Based on highly comparable experimental setups and 
analyses between the present study and the study by Näslund et al. 
(2017), we conclude that while both naproxen and diclofenac cause 
similar types of effects in fish, the hazards associated with diclofenac 
exposure in fish appear to be considerably higher than for naproxen. 
To interpret the observed differences in effect levels between na-
proxen and diclofenac, one could also apply a read-across approach, 
assuming a similar relative potency at the molecular target as in hu-
mans (HTPC, Table 3). This approach has been applied in many studies 
with pharmaceuticals in fish, since it was first described by Huggett 
et al. (2003), referred to as “the fish plasma model”. As plasma con-
centrations in the exposed stickleback are not known, this put some 
limitations for interpretability and an evaluation of how reasonable it is 
to observe effects at the measured whole body internal concentrations. 
As the distribution volumes (VD) in humans are low for both diclofenac 
and naproxen (0.1−0.2 L/kg, (Davies and Anderson, 1997a, b)), it 
suggests that a relatively large proportion of the drug is present in 
plasma, at least in humans. Hence, plasma concentrations (which are 
challenging to analyze in such small fish as sticklebacks) are likely to be 
higher than the measured whole-body concentrations. This is supported 
by Brown et al. (2007); Fick et al. (2010a) and Lahti et al. (2011) where 
all report considerably higher BCFs between water and blood plasma in 
rainbow trout than the BCF we found between water and whole-body of 
stickleback for diclofenac. The ratio between the BCF of diclofenac from  
Näslund et al. (2017) and the BCF of naproxen in our present study 
(0.3/0.07 ≈ 4.3; water to whole-body) are in very good agreement with 
the ratio based on their lipophilicity and the theoretic model for bio-
concentration (Table 3, 110/24 ≈ 4.6) (Fitzsimmons et al., 2001). In 
line with our findings, Lahti et al. (2011) also reported a similar BCF 
ratio between diclofenac and naproxen (4.9/1.4 = 3.5, 5.7/1.6 ≈ 3.6; 
water to blood plasma in rainbow trout). Together, this supports our 
observation that diclofenac bioconcentrates more than naproxen does 
in fish. 
The bioconcentration factor from water to whole-body was only 
0.07 for naproxen while it was 0.3 for diclofenac in a directly com-
parable experimental setup (Näslund et al., 2017). Using the human 
therapeutic plasma concentration (HTPC) as a measure of potency 
suggest that diclofenac would be considerably more potent, with a 
HTPC 40 times lower than naproxen. Taking both bioconcentration 
potential and HTPC into account suggest that diclofenac is over 170 
times more potent than naproxen in fish. This is in reasonable agree-
ment with one histopathological endpoint with a LOEC for diclofenac 
65 times lower than for naproxen. While difficult to pinpoint exactly 
how large the difference in potency is, it could even be greater than 65 
times, as effects by diclofenac were observed at the lowest concentra-
tion tested in our previous study. Additionally, the number of fish in 
each aquaria was higher in the naproxen study resulting in higher 
statistical power, still a much higher LOEC was found. Effects on kidney 
histology were observed at a whole-body concentration corresponding 
to 0.28 % of the HTPC for diclofenac and 0.1 % for naproxen. 
One of the main findings in this study is increased renal hemato-
poietic hyperplasia. We used the same classification system as in our 
previous study (Näslund et al., 2017) and the grading of the findings 
was made by the same trained fish pathologist (JN). We also used coded 
slides and the histopathological classification was verified by statistical 
comparisons. However, this is not the first mentioning of renal effects in 
Fig. 8. Expression fold change (2−ΔΔCT ) of hepatic c7, cyp1A, gr and sod-1 mRNA in the different aquaria in relation to the control group. One dot represent one fish 
and the fish in the same aquarium are depicted on top of each other. Thus, the three aquarium replicates in the same treatment group are clustered beside each other. 
The statistical analyses are based on ΔCT-values. Asterisks indicate significant differences to the control group, two-tailed test. A(c7): *** p ≤ 0.001; B(cyp1A): * p = 
0.035; C (gr): ** p = 0.007; D (sod-1): * p = 0.018. 
J. Näslund, et al.   Aquatic Toxicology 227 (2020) 105583
8
fish by naproxen. Górny et al. (2019) recently claimed that naproxen 
have a negative influence on the kidneys in zebrafish, referring to the 
study by Ding et al. (2017). But Ding et al. (2017) did not investigate 
any renal effects in fish, but in turn cited Stancova et al. (2015b) and  
Chattopadhyay et al. (2016) regarding renal effects in zebrafish. 
However, neither one of these studies investigated effects of naproxen 
on fish kidneys, nor do they cite any other studies that do so. Hence, to 
the best of our knowledge, this is the first histopathological evaluation 
of the kidney in fish exposed to naproxen. We also observed such effects 
in sticklebacks exposed to diclofenac, and Schwaiger et al. (2004) 
showed the same type of effects in rainbow trout exposed to diclofenac 
although referring to it as “interstitial nephritis” (Schwaiger et al., 
2004). It is therefore plausible that the observed renal hematopoietic 
hyperplasia is a common effect by NSAIDs in fish. We suggest that this 
terminology should be used rather than “interstitial nephritis” as there 
is no apparent signs of inflammation (Näslund et al., 2017). 
Another shared and rather specific effect of both naproxen and di-
clofenac in fish are defects on the jaws. Stancova et al. (2014) exposed 
tench (Tinca tinca) larvae to a mixture of diclofenac, ibuprofen and 
carbamazepine and reported lesions in the lower jaw. As only a mixture 
was studied, it could not be concluded with certainty if the effects was a 
consequence of the NSAID or the carbamazepine exposure or a com-
bination effect. We have showed that jaw lesions indeed can be caused 
by diclofenac exposure in sticklebacks (Näslund et al., 2017). A more 
comprehensive study regarding mandibular effects of diclofenac on 
Japanese medaka (Oryzias latipes) was recently published by Yokota 
et al. (2018). Effects were observed on dental bones, hypohyals of the 
mandible and the premaxillae whereas no visible abnormalities were 
seen in any other skeletal bones. Although other studies have not in-
vestigated the characteristics of jaw lesions in such detail, this appears 
to be in agreement with both the findings in tench and stickleback 
exposed to diclofenac and our present findings in sticklebacks exposed 
to naproxen. We have earlier speculated that both renal hematopoietic 
hyperplasia and jaw lesions could potentially be a consequence of 
secondary infections caused by an impaired immune systems due to 
diclofenac exposure (Näslund et al., 2017). The accumulating ob-
servations of specific changes across different studies, laboratories, 
species and NSAIDs suggest that these rather are direct effects, linked to 
the shared mode of action of NSAIDs. Yokota et al. (2018) proposed that 
diclofenac affects bone remodeling in the lower jaws by disrupting 
osteoclast function, but the mechanism involved are still unknown. 
Table 4 
Comparison of experimental designs, LOECs and BCFs for exposure studies with 
stickleback to either diclofenac (Näslund et al. (2017)) or naproxen (present 
study).      
Diclofenac Naproxen  
Experimental design   
Exposure concentration 
(nominal, μg/L) 
0, 5, 20, 80, 320 0, 20, 80, 320, 1280 
Exposure concentration 
(measured, μg/L) 
0, 4.6, 22, 82, 271 0, 18, 70, 299, 1232 
Duration 28 d (21 d for 271 
μg/L) 
27 d (21 d for 1232 
μg/L) 
Number of fish/aquaria 12 20 
Number of replicate aquaria/ 
treatment 
3 3 
Aquaria water temperature 15.7−17.6 °C 15.0−16.6 °C 
LOEC   
Renal hematopoietic 
hyperplasia1 
4.6 μg/L 299 μg/L 
Hepatic gene expression (c7) 22 μg/L 299 μg/L 
Condition factor 271 μg/L 1232 μg/L 
Mortality 271 μg/L 299 μg/L 
Jaw lesions1 271 μg/L 299 μg/L 
BCF (water to whole-body) 0.3 0.07 
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The hepatic gene expression of c7 also appears to be a quite char-
acteristic response to NSAIDs. It showed a clear concentration-depen-
dent response both to naproxen and diclofenac (Cuklev et al., 2011;  
Näslund et al., 2017). The c7 protein is a part of the complement 
system, which is a component of the innate immune system. It forms a 
membrane attack complex together with other complement component 
proteins which lead to lysis of foreign cells (Delves and Roitt, 2011). It 
has been shown that the complement components are connected to the 
arachidonic acid pathway (Hänsch et al., 1984) and it is therefore 
reasonable that NSAID exposure could affect c7. The observations here 
supports the analyses of c7 mRNA as an exposure biomarker for 
NSAIDs, although specificity should ideally be evaluated further. 
In contrast to the more specific responses mentioned above, some of 
the effects were more unspecific. We observed a decreased hepatocel-
lular vacuolation in naproxen exposed fish. Since the vacuoles can both 
consist of lipids and/or glycogen with special stains/techniques needed 
to verify their content, the term vacuolation covers both findings. 
Decreased vacuolation in fish is a consequence of either direct hepatic 
toxicity or secondary to stress and/or disease which causes a decreased 
body condition (Wolf and Wolfe, 2005). Diclofenac has also been shown 
to cause decreased hepatocellular glycogen in fish (Wolf et al., 2014). 
However, both in the present study and the study by Wolf et al. (2014), 
the effect were only significant at a concentration ≥ 1000 μg/L. Hence, 
hepatocellular vacuolation is not likely to be a response found under 
realistic field exposure scenarios, and if it is, it could have many other 
causes. 
As discussed above, hepatic gene expression of c7 seems to be a 
relatively sensitive marker to NSAID exposure, with at least a plausible 
mechanistic connection to their mode of action. In contrast, effects on 
the expression of many other genes have been reported as well, often at 
higher concentration and without such links to prostaglandin synthesis 
or inflammatory responses. For example, we found here that the ex-
pression of cyp1A decreased, an effect not observed for diclofenac 
(Näslund et al., 2017). One may note that we observed effects only at 
the highest tested concentration of naproxen and such high con-
centrations were not tested in the diclofenac experiment. Stancova et al. 
(2015b) accordingly found no effect on cyp1A1 (or sod2) in zebrafish 
exposed to 100 μg/L naproxen. Hong et al. (2007) reported increased 
levels of both cyp1A, p53 and vtg in Japanese medaka (Oryzias latipes) 
at a very low concentration (1 μg/L) of diclofenac. As their conclusion is 
based solely on the analyses of elevated levels in one single sample of 
three pooled fish, we think there are good reasons to disregard this 
report. In a much more well-designed study, Kwak et al. (2018) in-
vestigated effects of naproxen on gene expression in Japanese medaka 
across a range of concentrations, and found effects on vitellogenin 
(vtg1), the estrogen receptor (erb2) and cyp17 but only at concentrations 
of 500−5000 μg/L and higher. Accordingly, we observed no effects on 
vtg in the livers of sticklebacks exposed to up to 1232 μg/L. Taken to-
gether, in the genes analyzed so far, only c7 stands out as a gene that is 
consistently affected by different NSAIDs in different species and at 
relatively low concentrations. 
A very recent study investigated the effects of naproxen in zebrafish 
on a large range of endpoints related to thyroid disruption (Xu et al., 
2019). The authors motivate their study by referring to Bishnoi et al. 
(1994), a non-randomized clinical study in humans with NSAID-treated 
disease. Bishnoi et al. (1994) provide circumstantial, inconclusive evi-
dence for effects of NSAIDs on the thyroid system in humans. Samuels 
et al. (2003), on the other hand, performed a randomized clinical study 
in healthy humans and found no evidence that naproxen affect thyroid 
hormone levels. Having said this, there is support that some other 
NSAIDs can affect thyroid homeostasis and one could hence not exclude 
that similar effect could occur after naproxen exposure. In the study on 
zebrafish, Xu et al. (2019) investigated thyroid hormone levels (total T3 
and T4), bioconcentration, gene expression (cyp1A and cyp3A) and 
enzyme activities (EROD) potentially involved in/reflecting elimination 
of naproxen. The expression of a large range of genes specifically 
related to the hypothalamic-thyroid-axis was also investigated. For a 
large set of endpoints (cyp1A, cyp3A, EROD, T4, dio2, nis, pax8, tg, tpo, 
trβ, ttr, ugt1ab, TTR) the authors report dose-response related, sig-
nificant effects already at the lowest concentration tested (0.1 μg/L) 
although there is some inconsistency between text and figures. This 
exceptionally low effect concentration is much lower than all other 
studies investigating the effects on naproxen in fish. The claims of 
cyp1A effects stands in strong contrast to our present study where LOEC 
for cyp1A is 1232 μg/L, i.e. more than a 12 000 times difference in 
potency and the study by Stancova et al. (2015b) where no significant 
effects were found on cyp1A1 in zebrafish – the same species - exposed 
to naproxen up to 100 μg/L. Furthermore, the bioconcentration data 
reported by Xu et al. (2019) is unexpected, as exposure to 0.1, 1 and 10 
μg/L all resulted in a largely similar whole-body concentration (i.e. the 
bioconcentration factor decreased more than 50 times as the exposure 
concentration increased from 0.1 to 10 μg/L). In contrast, we found a 
stable (and much lower) bioconcentration factor across all exposure 
concentrations, as did (Lahti et al., 2011). Based on our own experi-
ences and similar studies, we find variances of the gene expression data 
(for all 14 investigated genes) in the study by Xu et al. (2019) to be very 
small. Taken together, this led us to contact the authors to ask for 
clarifications, but without reply. When we involved the editor of the 
journal, we received the reply from the authors that most of the original 
data had been lost in a fire accident and could not be provided. We 
think this is highly unfortunate, as we think an in-depth scrutinization 
(and independent replication of the experiment) is warranted (Harris 
et al., 2014) in order to allow an evaluation of the findings before any of 
these results are incorporated into any risk assessment or management 
efforts. 
In general, histopathological examinations of fish exposed to na-
proxen is sparse, with only three published papers (Stancova et al., 
2015a; Li et al., 2016; Sehonova et al., 2017). Stancova et al. (2015a) 
treated zebrafish with naproxen for 14 days and reported “obvious 
changes to the gills and liver” at 1 μg/L. There is, however, no quan-
tification of any lesion and it is not clear if the assessment was per-
formed in a blinded manner. Furthermore, it is very difficult to evaluate 
the provided histological images due to low magnification and poor 
resolution. The only obvious difference is that the gill sections vary in 
staining intensity/thickness. None of the stated pathological changes 
(hyperemia, widening of leaflet’s apex and desquamation of leaflet’s 
epithelium) can with certainty be identified in the figures. The authors 
also report separation of hepatocytic trabeculae in the liver, but these 
are most likely artefacts due thick sections and subsequent cracks. In 
conclusion, our judgement is that none of the claimed histopathological 
findings can be verified by the provided data. Stancova et al. (2015a) 
also report changes in enzyme activities of whole-body homogenates, 
but these are not consistent over time, nor do they follow clear con-
centration-response relationships. Li et al. (2016) studied acute toxicity 
in zebrafish (Danio rerio) at 10−240 mg/L and reported liver damage. 
Judging by the figures in the paper, the quality of the slides are poor 
and only a qualitative assessment was made. The lack of quantification 
thus precludes statistical comparisons. However, the described histo-
pathological changes seen in the liver may very well be present but the 
interpretation is challenging. Sehonova et al. (2017) reports histo-
pathological changes in skin and gills of common carp (Cyprinus carpio) 
at exposure concentration and lengths of exposure similar to our pre-
sent study. While the authors claim there are differences in the number 
of mucous cells and gill lamella deformations, no quantification is 
presented. As information lack with regards to histopathological 
methodology, it is again difficult to interpret the results. 
Reported concentration of both naproxen and diclofenac in WWTP 
effluents vary greatly, even within Sweden. Internationally, naproxen 
have occasionally been reported at levels up to 33.9 μg/L (Metcalfe 
et al., 2003) but levels around or below 1 μg/L are much more frequent 
(Tixier et al., 2003; Lishman et al., 2006; Loos et al., 2013). A Swedish, 
national surveillance study report naproxen levels of 1.2–1.8 μg/L (Fick 
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et al., 2010a) but in 2016 and 2017, levels of only 21−391 ng/L were 
detected in the effluent from three large WWTPs in the Stockholm re-
gion (Janusinfo Region Stockholm, 2019). Substantial differences have 
also been reported for diclofenac, with μg/L concentrations reported in 
some studies (Andreozzi et al., 2003; Stülten et al., 2008; Gros et al., 
2010) and low ng/L concentrations in others (Loos et al., 2013; Yu 
et al., 2013). While all this may reflect real concentrations, the use of 
different analytical methods, in different labs, variable consumption 
patterns and other factors that differ between sampling times and 
sampling points are also likely to contribute to variability. To enable 
direct comparisons of concentrations, studies that analyze both na-
proxen and diclofenac in the very same samples in parallel with the 
same methodology and where the sales volumes are known are there-
fore preferred. Region Stockholm has analyzed both NSAIDs in influents 
and effluents of three major WWTPs over several years (Janusinfo 
Region Stockholm, 2019). Focusing on their recent data from 2016 and 
2017, naproxen (mean value of 1674 ng/L) dominated over diclofenac 
(mean value 196 ng/L) in influents, in accordance with more kilograms 
sold and a larger proportion of unchanged drug excreted (Table 3). 
Effluent concentrations were more similar (naproxen mean value of 121 
ng/L, diclofenac mean value of 149 ng/L). These data also reveal a 
much more efficient removal of naproxen and this is in agreement with 
a range of other studies of NSAIDs in Swedish WWTPs (Falås et al., 
2012). Thus, while absolute levels of both naproxen and diclofenac in 
treated WWTP effluents (and hence surface waters) are difficult to de-
rive from the literature, there is reasonably good support that with 
current usage and treatment technologies in Sweden, expected con-
centrations of diclofenac are similar or somewhat higher than na-
proxen. 
It is clear that exposure to naproxen can cause adverse effects in fish 
if exposure is sufficiently high. However, we only observed effects at 
concentrations of 299 μg/L and higher. Diclofenac on the other hand 
had a LOEC of 4.6 μg/L in a directly comparable study (Näslund et al., 
2017). Given the discussion above on the exposure from these NSAIDs, 
the safety margin for naproxen is considerably greater than for diclo-
fenac. However, if surface water concentrations remain below 0.1 μg/L 
(corresponding to the proposed Environmental Quality Standard for 
diclofenac under the European Water Framework Directive; (EU, 
2012)) the risks is probably low or very low for both. 
Controlled exposure studies to individual chemicals, such as the 
present one, are limited in that they rarely take into account co-ex-
posure to other chemicals, variability in bioavailability that depends on 
water chemistry or alternative exposure routes (e.g, via the food chain). 
A way forward to investigate if there indeed are effects of diclofenac, 
naproxen and/or other similarly acting NSAIDs on fish in the environ-
ment, we propose dedicated effect studies of fish exposed to treated 
sewage effluent in controlled aquaria experiment, in fish caged up-and 
down-stream from sewage treatment plants and in wild fish, as all three 
approaches have their pros and cons. As renal hematopoietic hyper-
plasia, jaw malformations and induction of hepatic c7 expression ap-
pears to be rather consistent effects of diclofenac and naproxen ex-
posure, we suggest these effects should be monitored. In combination 
with analyses of NSAID levels in plasma or tissues, such an approach 
could add substantially to our understanding of risks. 
Although risks are greater for diclofenac given available hazard data 
and current use of NSAIDs in Sweden, it is critical to investigate what a 
substitution would mean in terms of environmental exposure levels, 
particularly as a typical dose of naproxen is five times higher than for 
diclofenac (Table 3). Sweden provides a good study case, as there is 
excellent data on total sales and corresponding measured levels in the 
WWTP effluents. As for 2016−2017, sales for naproxen were five times 
higher in terms of kilogram sold active substance (Table 3). However, 
counted as sold doses, the two drugs are very similar (Table 3). If all 
current sales of diclofenac were replaced by naproxen, the sales of 
naproxen would therefore increase two-fold and actual effluent levels 
would likely increase proportionally. Reciprocally, if all naproxen were 
replaced by diclofenac, the sales and the concentrations of diclofenac 
would be expected to increase by two-fold. The difference in hazard is 
much larger than two-fold. Hence, based on the hazard data presented 
here, replacing diclofenac with naproxen would decrease risks to fish. 
While the number of ecotoxicological studies reporting effects levels 
of different pharmaceuticals is increasing, it does not automatically 
mean that the amount of relevant, reproducible and comparable data is 
increasing at the same pace. To facilitate a thorough comparison be-
tween diclofenac and naproxen we have performed and reported the 
results of two very similar studies (Näslund et al., 2017, this study). 
Although naproxen and diclofenac produce similar effects in fish, the 
environmental hazards and risks are lower for naproxen compared to 
diclofenac based on available data. A way to manage risks to fish would 
therefore be to substitute diclofenac with naproxen when it provides an 
adequate alternative from a clinical point-of-view. 
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